Celecoxib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Celecoxib

Examples of brand names: Celebrex [DE]

ATC code: M01AH01

Main use (for orientation): Pain; inflammation

Documented research summary

The human study concerns a cannabis use disorder model and provides no benefit. Numerous direct preclinical combination effects strongly depend on cells, models and formulations; synergy with free substances must not be adopted for liposomes or human therapy. A CYP2C9-related exposure increase from cannabinoids has not been clinically quantified.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

5 separately recorded findings. Each statement applies to its documented study context.

Cannabis/THC – clinical signals

Finding ID: B0372

Type of result: Clinical signals

Observation: Celecoxib improved subjective but not objective sleep, increased craving and showed no overall advantage in withdrawal/self-administration.

Mechanism: COX2 inhibition in a cannabis-use/withdrawal model.

Study type: Placebo-controlled crossover laboratory study

Context studied: 15 daily cannabis smokers, celecoxib 200 mg twice daily, two 11-day periods, cannabis containing 5.3% THC; >14-day washout.

Clinical interpretation: No cannabis use disorder recommendation or pharmacokinetic evidence

Limitations and uncertainties: Abstract only; intoxication phase present, but its individual results not detailed in the abstract. Do not claim general antagonism of the high.

Original sources for this finding: Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. [C_PR_35754107]

CBD – laboratory and animal studies

Finding ID: B0373

Type of result: Preclinical evidence

Observation: Free CBD plus celecoxib showed concentration-dependent synergy in U138MG; liposomal formulation in 2025 showed no clear additive/synergistic effect; liposomal formulation in 2026 showed only an animal tumour trend, not proven in-vivo synergy.

Mechanism: Cell/formulation-dependent pharmacodynamics, ROS/Nrf2/NFκB/Wnt.

Study type: Cell culture and subcutaneous xenograft mouse model

Context studied: Free substances for 24 hours at 1–100 µM, synergy mainly at 10–20 µM; follow-up assays at total concentrations of 5/10 µM. In 2026 n=5/group, CBD 10 plus celecoxib 40 mg/kg intratumorally on days 8, 11, 14, 17 and 20.

Clinical interpretation: No cancer-treatment recommendation

Limitations and uncertainties: In-vivo and in-vitro formulations in 2026 not identical; unblinded, no pharmacokinetics/biodistribution/orthotopic model; no superior synergy across all markers; normal cells also showed dose-dependent toxicity. 2,5-DMC is a different drug, not celecoxib.

Original sources for this finding: Synergistic combination of cannabidiol and celecoxib or 2,5-dimethylcelecoxib exerts oxidative stress-mediated cytotoxicity and mitigates glioblastoma invasiveness. [C_PR_41089524]; The Anti-Glioblastoma Effects of Novel Liposomal Formulations Loaded with Cannabidiol, Celecoxib, and 2,5-Dimethylcelecoxib. [C_PR_40871052]; Cannabidiol- and Celecoxib-Loaded Liposomes as a Strategy to Modulate Redox and Inflammatory Signaling in High-Grade Glioma: A Preliminary In Vivo Study. [C_PR_42511566]

CBD – laboratory and animal studies

Finding ID: B0374

Type of result: Preclinical evidence

Observation: Celecoxib enhanced the anti-apoptotic CBD effect in normal human keratinocytes with/without UVB.

Mechanism: COX2-dependent modulation of cell apoptosis.

Study type: In-vitro experiment

Context studied: CBD 4 µM, celecoxib 20 µM, UVB 60 mJ/cm², 24 hours, 3 cultures.

Clinical interpretation: No clinical interaction quantified

Limitations and uncertainties: Cell-specific direction, opposite to tumour-cell apoptosis; not a clinical skin-protection recommendation.

Original sources for this finding: Influence of Inhibition of COX-2-Dependent Lipid Metabolism on Regulation of UVB-Induced Keratinocytes Apoptosis by Cannabinoids. [C_PR_35740969]

THC – laboratory and animal studies

Finding ID: B0375

Type of result: Preclinical evidence

Observation: THC plus celecoxib showed stronger effects on spatial learning and less THC-associated neuroinflammation than THC alone in an Alzheimer's mouse model.

Mechanism: COX2/nervous-system pharmacodynamics.

Study type: Animal experiment

Context studied: THC 3 mg/kg, celecoxib 1 mg/kg; 2025 abstract, publisher metadata confirmed.

Clinical interpretation: No human prevention or Alzheimer's treatment can be inferred

Limitations and uncertainties: Abstract incorrectly equates nabilone with THC; not adopted. Clinical extrapolation unproven.

Original sources for this finding: A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease. [C_PR_41452714]

CBD – laboratory and animal studies

Finding ID: B0376

Type of result: Preclinical evidence

Observation:Combining individually ineffective doses produced antidepressant/anxiolytic-like effects in acute mouse models. In microglial cell cultures, CBD enhanced celecoxib-induced inhibition of TNFα and IL-1β secretion; other stress models used different dosing regimens.

Mechanism: Preclinical anxiolytic/antidepressant-like pharmacodynamics.

Study type: Animal and cell experiments; abstract

Context studied: Acute celecoxib 10/CBD 5 mg/kg; other LPS/CSDS regimens differed.

Clinical interpretation: No human-treatment recommendation

Limitations and uncertainties: Abstract only; tests do not establish antidepressant efficacy in humans.

Original sources for this finding: A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects. [C_PR_36520610]

References and access status

[C_LABEL_D0166] GENERIC DRUG (CELECOXIB) CAPSULE [SIMCERE OF AMERICA, INC.]

Original source / bibliographic reference

Authors: SIMCERE OF AMERICA, INC.

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_41452714] A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.

Original source / bibliographic reference

Authors: Zhang J, Zhu D, Hu M, Pan M, Chen C.

Year: 2025

Source type: Primary source, abstract read

DOI: 10.14336/ad.2025.1206

PMID: 41452714

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_42511566] Cannabidiol- and Celecoxib-Loaded Liposomes as a Strategy to Modulate Redox and Inflammatory Signaling in High-Grade Glioma: A Preliminary In Vivo Study.

Original source / bibliographic reference

Authors: Rybarczyk A, Majchrzak-Celińska A, Piwowarczyk L, Tomczak S, Wronka D, Karlik A, Przybył Ł, Krajka-Kuźniak V.

Year: 2026

Source type: Primary source, full text read

DOI: 10.3390/ijms27146220

PMID: 42511566

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_40871052] The Anti-Glioblastoma Effects of Novel Liposomal Formulations Loaded with Cannabidiol, Celecoxib, and 2,5-Dimethylcelecoxib.

Original source / bibliographic reference

Authors: Rybarczyk A, Majchrzak-Celińska A, Piwowarczyk L, Krajka-Kuźniak V.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3390/pharmaceutics17081031

PMID: 40871052

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_41089524] Synergistic combination of cannabidiol and celecoxib or 2,5-dimethylcelecoxib exerts oxidative stress-mediated cytotoxicity and mitigates glioblastoma invasiveness.

Original source / bibliographic reference

Authors: Rybarczyk A, Majchrzak-Celińska A, Krajka-Kuźniak V.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3389/abp.2025.15062

PMID: 41089524

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_36520610] A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects.

Original source / bibliographic reference

Authors: Dinur E, Goldenberg H, Robinson E, Naggan L, Kozela E, Yirmiya R.

Year: 2024

Source type: Primary source, abstract read

DOI: 10.1089/can.2022.0225

PMID: 36520610

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_35754107] Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.

Original source / bibliographic reference

Authors: Haney M, Bedi G, Cooper ZD, Herrmann ES, Reed SC, Foltin RW, Kingsley PJ, Marnett LJ, Patel S.

Year: 2022

Source type: Primary source, abstract read

DOI: 10.1111/adb.13183

PMID: 35754107

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_35740969] Influence of Inhibition of COX-2-Dependent Lipid Metabolism on Regulation of UVB-Induced Keratinocytes Apoptosis by Cannabinoids.

Original source / bibliographic reference

Authors: Wójcik P, Biernacki M, Domian N, Žarković N, Skrzydlewska E.

Year: 2022

Source type: Primary source, full text read

DOI: 10.3390/biom12060842

PMID: 35740969

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_18028339] 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.

Original source / bibliographic reference

Authors: Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D.

Year: 2008

Source type: Primary source, abstract read

DOI: 10.1111/j.1471-4159.2007.05073.x

PMID: 18028339

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED12235269] Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.

Original source / bibliographic reference

Authors: Anikwue R, Huffman JW, Martin ZL, Welch SP.

Year: 2002

Source type: Publication; title and abstract reviewed

DOI: 10.1124/jpet.303.1.340

PMID: 12235269

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility